ºñ¼Ò¼¼Æ÷Æó¾Ï(Non-small cell lung cancer)¿¡¼ ¹ß¾Ï¼º º¯ÈÁø´Ü¿¡¼ ÆéŸÀ̵å ÇÙ»ê Ŭ·¥ÇÎ ¹× Á÷Á¢ ½ÃÄö½Ì ºñ±³ (Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis)
ÀÓ»óÁú¹®
|
ºñ¼Ò¼¼Æ÷Æó¾Ï(Non-small cell lung cancer, NSCLC) ¹ß¾Ï¼º º¯ÈÀÇ Å½Áö¸¦ À§ÇØ ÆéŸÀ̵å ÇÙ»ê Ŭ·¥ÇÎ (Peptide Nucleic Acid Clamping, PNA) °ú Á÷Á¢ ½ÃÄö½Ì(Direct Sequencing, DA) ºñ±³ÇÑ °á°ú°¡ ÀÖ½À´Ï±î?
|
±Ù°Å±â¹Ý ´äº¯
|
PNA Ŭ·¥ÇÎÀº NSCLCÀÇ ¹ß¾Ï¼º º¯È¸¦ Áø´ÜÇϱâ À§ÇØ DSº¸´Ù º¸´Ù ³ôÀº ¹Î°¨µµ¸¦ ³ªÅ¸³»¾ú´Ù. º» ¿¬±¸°á°ú¸¦ ÅëÇÏ¿© PNA Ŭ·¥ÇÎÀÌ DAº¸´Ù ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚÀÇ ÀÓ»óÁø´Ü¿¡ ´õ À¯¿ëÇÑ ¹æ¹ýÀÓÀ» º¸°íÇÏ¿´½À´Ï´Ù. |
¼ÁöÁ¤º¸
|
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis (2018). Yonsei Med J. 59(2):211-218. https://doi.org/10.3349/ymj.2018.59.2.211
|
¿¬±¸¸ñÀû
|
ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ ¹ß¾Ï¼ºº¯È±¸º°À» À§ÇÑ PNA Clamping°ú Direct Sequencing ºñ±³
|
¿¬±¸¼³°è
|
A systematic review and meta-analysis
|
¿¬±¸´ë»ó
|
NSCLC Patients (n=924)
|
Áúº´Æ¯¼º
|
ºñ¼Ò¼¼Æ÷Æó¾Ï(Non-small cell lung cancer)
|
Æò°¡ÁöÇ¥
|
EGFR mutations detection
Treatment responses to EGFR-TKIs
Sensitivity
Specificity
Receiver operating characteristic curves
|
ÁÖ¿ä°á°ú
|
ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ ¹ß¾Ï¼ºº¯È´Â Àüü 924¸íÀÇ Áø´Ü¹ÞÀº Æó¾ÏȯÀÚ(NSCLC) Áß¿¡ 340¸í(36.8%)°¡ PNA Clamping¿¡ ÀÇÇØ ±¸º°µÇ¾ú°í, DS¿¡ ÀÇÇØ Áø´Ü¹ÞÀº ȯÀÚ´Â ÀüüÀÇ 250¸í(27.1%)·Î ³ªÅ¸³µ´Ù. ¹Î°¨µµ¿ª½Ã PNA Clamping°ú DS°¡ °¢°¢ 0.93 [95% confidence interval (CI): 0.90-0.95] and 0.69 (95% CI: 0.64-0.73)·Î º¸°íµÇ¾ú´Ù.
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ
|
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)
Copyright © 2018. Medical Research Information Center (MedRIC) Editors
|